Quiz Answers: Treatments for presbyopia coming soon

November 19, 2020
Brooke Beery, Associate Editor
Brooke Beery, Associate Editor

Brooke Beery is Assistant Editor of Optometry Times®.

Optometry Times Journal, November digital edition 2020, Volume 12, Issue 11

1. What is the prevalence of presbyopia in the U.S.?

a. 5,000,000

b. 10,500,000

c. 50,000,000

d. 110,000,000

2. Miotics have few side effects.

a. True

b. False

3. Which of these devices uses pinhole optics (PHO)?

a. Revision Raindrop

b. Karama Inlay

c. FOV Tears

d. Allergan Presbysol

e. B and D

4. Which of these is not a pharmaco-refractive product?

a. Oraisis CSF-1

b. Presbyopia Therapies PRX-100

c. Allergan AGN

d. Eyenovia Micro-dose

e. All are pharmaco-refractive

5. What is the most common ingredient in current pharmaceutical drops for presbyopia being tested?

a. Dexamethasone

b. Pilocarpine

c. Bromfenac

d. Tropicamide

e. None of the above

6. Which of these is a device?

a. Oraisis CSF-1

b. Presbyopia Therapies PRX-100

c. Allergan AGN

d. Eyenovia Micro-dose

e. FOV Tears

7. Which is an active ingredient in PRX-100?

a. Pilocarpine

b. Tropicamide

c. Oxymetazoline

d. Polyethylene glycol

e. Diclofenac

This quiz accompanies THIS article from our November issue

download issueDownload Issue : November digital edition 2020

Related Content:

Presbyopia | Refractive Surgery